Curated, evidence-tiered listings of institutions, programs, startups, tools, and research across all four verticals. What's credible. What matters. What to do next.
Filter by Vertical
Filter by Type
Listed organizations (21) — verified, growing weekly
Open neuroscience research, brain atlases, and the Bezos-backed $400M Brain Health Accelerator.
Major brain-research institute spanning neuroscience, cognition, and neurotechnology.
Interdisciplinary institute connecting research across brain health, cognition, and disease.
Leading European basic-research institute on neural circuits and brain function.
Research center bridging autism, neurodiversity, AI, and assistive technology. Nashville, TN.
Research center on cognitive training and measurable lifelong brain health.
Largest U.S. autism study, building a genetic and phenotypic research cohort.
Major funder of autism and broader neuroscience research.
Nonprofit funding evidence-based autism research and supporting families.
Nonprofit moonshot funder backing breakthrough human-health and neuroscience programs.
Implantable brain–computer interface developing high-bandwidth neural implants.
Endovascular brain–computer interface (Stentrode) advancing through human trials.
Minimally invasive cortical interface aimed at restoring lost function.
High-data-rate cortical BCI targeting severe communication impairment.
Long-running BCI maker; the Utah Array underpins many human neural-interface studies.
Non-invasive neuroimaging (Kernel Flow) to measure brain activity at scale.
Digital therapeutics; EndeavorRx is an FDA-cleared game-based ADHD treatment.
Validated digital cognitive assessment used across research and clinical trials.
Computerized cognitive testing for clinical trials and healthcare.
Studied brain-training platform focused on measurable cognitive performance.
Integrated medical and therapy care model for autism and neurodevelopment.
No organizations match these filters yet.
Evidence Tiers
Peer-reviewed evidence, major institutional adoption, or regulatory clarity. Highest confidence.
Credible pilots, institutional backing, limited published data. Promising with caveats noted.
Early stage, marketing-heavy, unclear evidence. Listed with disclosure. Proceed with awareness.
Subscribe to The Brief for weekly updates on new directory entries and ecosystem developments.
Subscribe to The Brief